The Ministry of Health (MoH) has issued a binding
opinion agreeing to the reimbursement of a medicinal product for rare diseases
(LPVO) after the advisory board unanimously recommended approval.
Although the LPVO under assessment will be
reimbursed, it will still be necessary to submit an application for an
exceptional individual reimbursement under Section 16 of the Act on Public
Health...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
